Scilex Holding Company Unrealized Gain (Loss) on Derivatives
Scilex Holding Company (SCLX) reported Unrealized Gain (Loss) on Derivatives of -$2.60 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2022-02-24
- Scilex Holding Company unrealized gain (loss) on derivatives for fiscal 2021 was -$2.60M.
| Period end | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|
| 2021-12-31 | -$2.60M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |